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RUNX3 is a tumor suppressor for a variety of cancers. RUNX3 suppresses the
canonical Wnt signaling pathway by binding to the TCF4 ⁄ b-catenin complex,
resulting in the inhibition of binding of the complex to the Wnt target gene pro-
moter. Here, we confirmed that RUNX3 suppressed Wnt signaling activity in
several gastric cancer cell lines; however, we found that RUNX3 increased the
Wnt signaling activity in KatoIII and SNU668 gastric cancer cells. Notably, RUNX3
expression increased the ratio of the Wnt signaling-high population in the KatoIII
cells. although the maximum Wnt activation level of individual cells was similar
to that in the control. As found previously, RUNX3 also binds to TCF4 and b-cate-
nin in KatoIII cells, suggesting that these molecules form a ternary complex.
Moreover, the ChIP analyses revealed that TCF4, b-catenin and RUNX3 bind the
promoter region of the Wnt target genes, Axin2 and c-Myc, and the occupancy
of TCF4 and b-catenin in these promoter regions is increased by the RUNX3
expression. These results suggest that RUNX3 stabilizes the TCF4 ⁄ b-catenin com-
plex on the Wnt target gene promoter in KatoIII cells, leading to activation of
Wnt signaling. Although RUNX3 increased the Wnt signaling activity, its expres-
sion resulted in suppression of tumorigenesis of KatoIII cells, indicating that
RUNX3 plays a tumor-suppressing role in KatoIII cells through a Wnt-independent
mechanism. These results indicate that RUNX3 can either suppress or activate the
Wnt signaling pathway through its binding to the TCF4 ⁄ b-catenin complex by cell
context-dependent mechanisms.
R UNX3 is a member of the runt-related transcription factorRUNX family and was originally identified as a tumor
suppressor of gastric cancer development.(1–4) In approximately
80% of gastric cancers, RUNX3 expression is lost due to epi-
genetic silencing and mislocalization in the cytoplasm.(1,4,5)
Moreover, expression of RUNX3 in gastric cancer cells results
in suppression of tumorigenicity, while expression of the
mutant form of RUNX3 R122C found in human gastric cancer
does not affect tumorigenicity.(1,6) Consistently, gastric epithe-
lial cells derived from Runx3  ⁄ p53  ⁄ mice form
explanted tumors in nude mice.(7) The functional inactivation
of RUNX3 is frequently observed in other solid tumors,
including colon, pancreatic and lung cancers.(3,4) Taken
together, these results indicate that RUNX3 plays a tumor sup-
pressing role in a variety of cancers.
RUNX3 has multiple partners and is involved in diverse
signaling pathways.(3,4) Wnt signaling suppresses phosphoryla-
tion of b-catenin by GSK-3b, leading to the accumulation of
b-catenin in nuclei.(8) Accumulated b-catenin forms a com-
plex with TCF4, which induces the transcription of Wnt tar-
get genes by binding to the promoter regions of these genes.
The constitutive activation of Wnt signaling by genetic alter-
ation leads to gastrointestinal tumor development.(9–11) It has
previously been demonstrated in colon cancer cells that
RUNX3 binds to TCF4 through the runt domain, forming a
ternary complex of RUNX3, TCF4 and b-catenin, which
inhibits the binding of the complex to the promoter region of
Wnt target genes, thereby suppressing Wnt signaling.(12) The
expression of Wnt target genes is significantly increased in
Runx3  ⁄ mouse intestinal mucosa without any alteration
of the expression levels of TCF4 and b-catenin, and
Runx3 + ⁄ mice develop intestinal tumors.(12) Notably, the
association of the mutant RUNX3 R122C with TCF4 is
weaker than wild-type RUNX3; thus, R122C cannot suppress
Wnt signaling in Runx3  ⁄ gastric tumor cells.(13) These
results indicate that Wnt activation by RUNX3 downregula-
tion contributes to tumorigenicity.
In contrast to these findings, we present the unexpected find-
ing that RUNX3 activates Wnt signaling in KatoIII and
SNU668 gastric cancer cells. Interestingly, RUNX3 binds
TCF4 and b-catenin also in the KatoIII cells, and binding of
the complex to Wnt target gene promoter is more stable in the
presence of RUNX3, which may cause Wnt signaling activa-
tion. Accordingly, it is possible that RUNX3 can either sup-
press or activate Wnt signaling activity by binding to the
TCF4 ⁄b-catenin complex, and the direction of Wnt signaling
modulation may be regulated by a cell context-dependent
mechanism.
Cancer Sci | April 2014 | vol. 105 | no. 4 | 418–424 © 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd
on behalf of Japanese Cancer Association.
This is an open access article under the terms of the Creative Commons
Attribution-NonCommercial License, which permits use, distribution and
reproduction in any medium, provided the original work is properly cited and is
not used for commercial purposes.
Materials and Methods
Cell culture experiments. Human gastric cancer cell lines,
AGS (ATCC), AZ521, MKN45, KatoIII, (RIKEN, BioRe-
source Center, Tsukuba, Japan), SNU216, SNU484, SNU601,
SNU638, SNU668 and SNU719 (Korean Cell Line Bank,
Seoul, Korea) were cultured in RPMI1640 supplemented with
10% FBS. The cell proliferation rate was examined using the
Alamar Blue Cell Viability Reagent (Invitrogen, Carlsbad, CA,
USA). For the soft agar colony formation assay, cells were
suspended in 0.33% agarose contained in the medium and
seeded on 0.5% bottom agar. After 21 days of culture, soft
agar was stained with Giemsa solution (Wako, Osaka, Japan)
and colony numbers were scored.
Cells were transfected with pcDNA3, pcDNA-Flag-RUNX3
or pcDNA-Flag-RUNX3(R122C) vector.(6) KatoIII-R3 stable
cell line was constructed by transfection with pcDNA-RUNX3
and selected with G418 (Wako) at 100 lg ⁄mL. To knock
down gene expression, cells were transfected with Silencer
Select siRNA for RUNX3 or b-catenin (Ambion, Cambridge,
MA, USA).
To examine the Wnt activation level, cells were cotransfect-
ed with super 89 TOPflash or Super 89 FOPflash (Addgene,
Cambridge, MA, USA), together with pcDNA3, pcDNA-Flag-
RUNX3 or pcDNA-Flag-RUNX3(R122C).(6) At 24 h after
transfection, the luciferase activity was measured using a
Luciferase assay system (Promega, Madison, WI, USA).
Wnt suppression and activation. To inhibit Wnt signaling,
cells were treated with 10 lg ⁄mL of C59 (provided by
Dr David Virshup), which inhibits porcupine, a membrane-
bound O-acyltransferase required for Wnt palmitoylation.(14)
To activate Wnt signaling, conditioned media including Wnt3a
and Rspondin were prepared from L cells expressing Wnt3a
and 293T cells expressing Rspondin, respectively (provided by
Dr Marc Leushacke), and the conditioned media were supple-
mented at 10% volume in the culture medium.
Western blotting. A total of 10 lg of protein samples were
separated in 10% SDS-polyacrylamide gels. Antibodies for
RUNX3(5) or unphosphorylated b-catenin (Millipore, Billerica,
MA, USA) were used as the primary antibodies. The anti-b-
actin antibody (Sigma, St. Louis, MO, USA) was used as an
internal control, and the ECL detection system (GE Healthcare,
Buckinghamshire, UK) was used to detect the signals.
Real-time RT-PCR. Total RNA was extracted using ISOGEN
(Nippon Gene, Tokyo, Japan) and cDNA was constructed
using the Prime Script RT Reagent Kit (Takara, Tokyo, Japan).
Real-time RT-PCR was performed using the SYBR Premix Ex
TaqII (Takara) and Stratagene Mx3000P (Agilent Technolo-
gies, Santa Clara, CA, USA). The primers were purchased
from Takara.
Flow cytometry analysis. To examine the intracellular
RUNX3 and b-catenin levels, permeabilized cells were incu-
bated with the primary antibodies for total b-catenin (Sigma)
or RUNX3,(5) followed by the secondary antibodies for rab-
bit IgG-conjugated with Alexa 488 (Molecular Probes, Grand
Island, NY, USA) or mouse IgG-conjugated with Alexa 633
(Invitrogen), and examined using FACS Canto II (BD
Biosciences, San Jose, CA, USA). Cells were transfected
with a pcDNA-RUNX3-IRES-mGFP expression vector, in
which internal ribosome entry site (IRES) fragment from
pTRE3G-IRES (Clontech Laboratories, Mountain View, CA,
USA) and maxGFP cDNA from pmaxGFP (LONZA, Allen-
dale, NJ, USA) were subcloned to pcDNA-Flag-RUNX3,
and RUNX3-expressing cells were isolated using the FACS
Aria cell sorter (BD Biosciences, San Jose, CA, USA) to
collect GFP-expressing cells.
Immunocytochemistry. The cells were seeded on cover slips
and fixed in 4% paraformaldehyde, then permeabilized with
0.5% Triton X-100 in PBS. Antibodies against total b-catenin
(Sigma) or RUNX3 were used as the primary antibodies, and
anti-rabbit IgG Alexa 594 or anti-mouse IgG Alexa 488
(Molecular Probes) were used as the secondary antibodies.(5)
Immunoprecipitation. KatoIII cells were transfected with the
pcDNA-Flag-RUNX3 or pcDNA-Flag, and the cell lysates
were used for immunoprecipitation with anti-FLAG M2 aga-
rose (Sigma). Western blotting was performed using antibodies
against unphosphorylated b-catenin (Millipore), TCF4 (Santa
Cruz Biotechnology, Santa Cruz, CA), FLAG peptide or
b-actin (Sigma).
ChIP. The cells were treated with formaldehyde solution
(Wako) for crosslinking. ChIP was performed using the ChIP
Assay kit EZ ChIP (Millipore) and antibodies against TCF4
(Santa Cruz Biotechnology), unphosphorylated b-catenin
(Millipore), RUNX3(5) and mouse normal IgG. The primer
sequences for the c-Myc promoter were: 5′-TTGCTGGGTTAT
TTTAATCAT-3′ and 5′-ACTGTTTGACAAACCGCATCC-3′.(15)
For the Axin2 promoter, conserved TCF ⁄LEF binding sites are
localized in intron 1,(16) and Simple ChIP Human Axin2 Intron
1 Primers (Cell Signaling, Danvers, MA, USA) were used.
Statistical analysis. Statistical analyses were performed using
the unpaired Student’s t-test, with P-values <0.05 considered
significant.
Results
Wnt activation by RUNX3 expression in KatoIII and SNU668
cells. RUNX3 expression was detected by western blotting in
AZ521 and MKN45 cells, while it was not detected in other
gastric cancer cell lines (Fig. 1a). Consistently, high levels of
RUNX3 mRNA were detected in AZ521 and MKN45 cells by
RT-PCR (Fig. S1). We transiently transfected the RUNX3
expression vector to all gastric cell lines, and examined Wnt
signaling activity by luciferase reporter analysis. The Wnt sig-
naling activity was significantly decreased in SNU216,
SNU601, SNU638 and SNU719 cells, which was consistent
with the previous results.(12) However, RUNX3 expression
increased Wnt signaling activity in KatoIII and SNU668 cells
(Fig. 1b). Importantly, the R122C mutant form of RUNX3 that
is defective in the RUNX3 function did not change Wnt sig-
naling activity in these cells.(1,6) The KatoIII-R3, stable
RUNX3-expressing cells (Fig. S2) also exhibited an increased
luciferase activity, which was suppressed by RUNX3 siRNA
transfection (Fig. 1c). Moreover, Wnt activation levels
increased gradually in accordance with the amount of the
RUNX3 expression vector (Fig. 1d). Consistently, the expres-
sion levels of Wnt target genes, Sox4 and Axin2, increased
significantly in KatoIII and SNU668 cells by RUNX3 expres-
sion (Fig. 1e).
Notably, inhibition of endogenous RUNX3 expression by
siRNA in AZ521 significantly increased Wnt signaling activ-
ity, whereas RUNX3 siRNA transfection partially suppressed
Wnt signaling in MKN45 cells (Fig. 1e,f). These results, taken
together, suggest that RUNX3 suppresses or activates the Wnt
signaling in a cell context-dependent mechanism.
Saturation of ligand-induced b-catenin stabilization in KatoIII
cells. We further examined the RUNX3-induced Wnt activation
mechanism using KatoIII cells. In KatoIII cells, Wnt signaling
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is activated by b-catenin gene amplification.(17) Treatment of
control KatoIII cells with a Wnt ligand secretion inhibitor C59
significantly suppressed the endogenous Wnt signaling, indicat-
ing that Wnt ligand stimulation maintains the basal Wnt acti-
vation level (Fig. 2a). C59 treatment also decreased the
luciferase activity in the RUNX3-expressing KatoIII cells.
However, the ratio of the RUNX3-induced increase of lucifer-
ase activity in the C59-treated cells was similar to that in the
control cells; that is, approximately 4.5-fold the control levels.
Accordingly, it is possible that RUNX3 increases Wnt signal-
ing activity in KatoIII cells through a ligand-independent
mechanism.
We next examined the b-catenin levels of the RUNX3-
transfected cells by western blotting. Although the active
b-catenin levels were slightly increased both in the KatoIII-R3
cells and the RUNX3 vector-transiently transfected KatoIII
cells (Fig. 2b, Figs S2 and S3), the increase was not sufficient
to explain the marked increase of the TOPflash activity
(Fig. 1b).
The Wnt activation level increased significantly in 293T
cells following treatment with Wnt3a and ⁄or Rspondin
(Fig. 2c). However, treatment of KatoIII cells with Wnt3a
⁄Rspondin did not change the luciferase activity (Fig. 2d).
Consistently, the b-catenin high population measured by flow
cytometry was significantly increased in the 293T cells follow-
ing Wnt3a ⁄Rspondin treatment, while the b-catenin high popu-
lation in the KatoIII cells did not change following stimulation
with Wnt3a ⁄Rspondin (Fig. 2e,f). Therefore, it is possible that
the Wnt ligand-induced b-catenin stabilization level is satu-
rated in KatoIII cells, and RUNX3 activates Wnt signaling
through mechanisms other than b-catenin stabilization.
Increase of b-cateninHi population by RUNX3 expression in
KatoIII cells. We previously found that the Wnt activation level






Fig. 1. RUNX3-induced Wnt signaling activation.
(a) Western blotting of the RUNX3 expression in
gastric cancer cells. (b) Relative luciferase activity of
TOPflash ⁄ FOPflash in the respective gastric cancer
cells transfected with RUNX3 or R122C mutant
RUNX3 vector to the control vector-transfected
cells. (c) Luciferase activity of the TOPflash and
FOPflash in KatoIII-R3 cells and siRNA-transfected
KatoIII-R3 cells relative to the level in the parental
KatoIII cells. (d) Relative luciferase activity of
TOPflash ⁄ FOPflash in KatoIII cells transfected with
RUNX3 expression vector. (e) Relative expression
levels of the Wnt target genes, SOX4 and Axin2,
detected by RT-PCR in the RUNX3 vector-
transfected cells (red) or RUNX3 siRNA-transfected
cells (blue) to the control level. (f) Relative
luciferase activity of TOPflash ⁄ FOPflash in AZ521
and MKN45 cells transfected with RUNX3 siRNA to
the control level. (b–f) Bar graphs are shown as
mean  SD. *P < 0.05 versus control levels other-
wise indicated.
© 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd
on behalf of Japanese Cancer Association.
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Wnt-low state.(18) We thus examined the b-catenin levels of
the RUNX3-expressing cells using flow cytometry. When the
RUNX3 vector was transfected, the b-cateninHi population (top
50% level of the control in Fig. 3a, [left]) increased signifi-
cantly in the RUNX3Hi cells (78%: Q2 ⁄ (Q1 + Q2)), but not in
the RUNX3Lo cells (45%: Q4 ⁄ (Q3 + Q4)) (Fig. 3a [right], b).
Notably, the maximum b-catenin level in the RUNX3-trans-
fected cells was similar to that observed in the control
(Fig. 3a). We confirmed that transfection efficiency was not
different between b-cateninHi and b-cateninLo KatoIII cells
(Fig. S4). Immunocytochemistry of the RUNX3 vector-trans-
fected KatoIII cells showed that approximately 73% of the
RUNX3-positive cells were also positive for b-catenin,
whereas approximately 44% of the RUNX3-negative cells
were b-catenin positive (Fig. 3c). These results indicate that
RUNX3 expression increases the number of cells in the Wnt-
high population of KatoIII cells.
Tumor suppressing function of RUNX3 in KatoIII cells. It has
been reported that RUNX3 suppresses the tumorigenicity of
KatoIII cells.(19) Therefore, we reexamined the role of RUNX3
in the tumorigenicity of KatoIII cells. The RUNX3 vector-
transfected KatoIII cells exhibited slight but significant sup-
pression of cell proliferation at 48 and 72 h after seeding
(Fig. 4a), and RUNX3 siRNA increased proliferation KatoIII-
R3 cells at 48 h after seeding (Fig. S5).
We next transfected the RUNX3-IRES-mGFP expression
vector to KatoIII cells, and GFPHi and GFPLo cells were
isolated by cell sorting, corresponding to RUNX3Hi-express-
ing and RUNX3Lo-expressing cells, respectively (Fig. 4b).
Importantly, proliferation of GFPHi cells was significantly
suppressed compared with that of the GFPLo cells (Fig. 4c),
and we were unable to establish a GFPHi (RUNX3Hi) cell
line due to the limited proliferation. Moreover, RUNX3-
transfected KatoIII cells exhibited significant suppression of
soft agar colony formation (Fig. 4d), and the number of col-
onies larger than 0.1 mm in diameter was significantly
decreased to 5.6% of the control (Fig. 4e). Moreover,
expression of cell cycle inhibitor p21WAF1/Cip1 was increased
significantly in KatoIII cells by RUNX3 expression (Fig. 4f),
which was consistent with previous report.(20) These results
indicate that RUNX3 plays a tumor-suppressing role in
KatoIII cells, and that RUNX3-dependent Wnt activation is
not sufficient to maintain the tumorigenicity of RUNX3Hi
KatoIII cells.
Binding of the RUNX3 and TCF4 complex to the Wnt target
gene promoters in KatoIII cells. It has previously been shown
that RUNX3 binds to TCF4 ⁄b-catenin complex, which sup-
presses the binding of the complex to the Wnt target gene pro-
moters.(12,13) Notably, immunoprecipitation experiments
revealed that RUNX3 bound b-catenin and TCF4 also in the
RUNX3-transfected KatoIII cells (Fig. 5a), suggesting that
RUNX3, TCF4 and b-catenin form a ternary complex also in
KatoIII cells.
We next performed ChIP analyses to examine whether the
binding of the TCF4 ⁄b-catenin complex to the promoter of
the Wnt target genes was suppressed in the RUNX3-express-
ing KatoIII cells. In the control KatoIII cells, TCF4 and
b-catenin bound to the Axin2 and c-Myc gene promoters
(Fig. 5b, Lanes 1 and 4). Importantly, TCF4 and b-catenin
also bound to the Axin2 and c-Myc gene promoters in the
RUNX3-expressing KatoIII cells, and their band intensities
were higher than those of the control cells (Fig. 5b, Lanes 2
and 5). Consistently, ChIP-based real-time PCR analysis




Fig. 2. Saturation of ligand-induced b-catenin
stabilization in KatoIII cells. (a) Luciferase activity of
TOPflash ⁄ FOPflash in KatoIII cells transfected with
RUNX3 or control vector in the absence or presence
of the C59 relative to the control cell level
(mean  SD). *P < 0.05. (b) Western blotting for
active b-catenin and RUNX3 in KatoIII cells
transfected with RUNX3 vector. (c,d) Relative
luciferase activity of TOPflash ⁄ FOPflash in the 293T
cells (c) and KatoIII cells (d) treated with Wnt3a
and ⁄ or Rspondin. (mean  SD). *P < <0.05 versus
control level. (e,f) Flow cytometry analyses of
b-catenin in the control cells (left) and cells treated
with Wnt3a ⁄ Rspondin (right) in 293T (e) and KatoIII
cells (f). The proportion (%) of the b-cateninHi
population (top 5% level of the control) is
indicated.
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c-Myc gene promoters that bound TCF4 and b-catenin was
significantly higher in the RUNX3-expressing KatoIII cells
compared with the control cells (Fig. 5c,d). Moreover, we
confirmed that RUNX3 bound the Axin2 and c-Myc gene pro-
moters in the RUNX3-expressing KatoIII cells (Fig. 5b,
Lanes 2 and 5, and Fig. 5c,d). In contrast, the R122C mutant
RUNX3 did not significantly increase the binding of TCF4
and b-catenin to the Axin2 and c-Myc gene promoters
(Fig. 5b, Lanes 3 and 6, and Fig. 5c,d). These results indicate
that the complex consisting of RUNX3, TCF4 and b-catenin
binds to the promoter of Wnt target genes in KatoIII cells in
a more stable fashion than the TCF4 ⁄b-catenin complex,
which may increase the proportion of the Wnt-high cells in
the RUNX3-expressing KatoIII cells.
Discussion
It has been demonstrated that RUNX3 binds to TCF4 and
b-catenin, resulting in suppression of the binding of TCF4
to the Wnt target gene promoters, thereby suppressing the
Wnt signaling.(12) In the present study, we found that
RUNX3 increased the Wnt activity in KatoIII and SNU668
cells. RUNX3 bound TCF4 and b-catenin also in the KatoIII
cells, and the complex was stabilized to bind Wnt target
gene promoter, which is in contrast to the previous find-
ings.(12,13)
The important question is how RUNX3 activates Wnt sig-
naling in KatoIII and SNU668 cells. It is known that b-cate-




Fig. 4. Suppression of tumorigenicity of KatoIII
cells by RUNX3. (a) Relative cell proliferation rates
of RUNX3 vector-transfected KatoIII cells and
control vector-transfected cells at the indicated
time points (mean  SD). *P < 0.05. (b) Flow
cytometry analyses for GFP expression in the
control (left) and RUNX3-IRES-mGFP-transfected
(right) KatoIII cells. (c) Representative photographs
of GFPHi (left) and GFPLo (right) cells sorted from
RUNX3-IRES-mGFP-transfected KatoIII cells after
culture for 6 days. (d) Representative photographs
of the soft agar colonies of the control (left) and
RUNX3-transfected KatoIII cells (right). (e) The
number of soft agar colonies per dissecting
microscopic field. *P < 0.05. (f) Relative p21 mRNA
expression level in RUNX3 vector-transfected KatoIII




Fig. 3. The increased b-cateninHi population in
RUNX3-expressing KatoIII cells. (a) Flow cytometry
analyses of b-catenin and RUNX3 expression in the
control (left) and RUNX3-transfected (right) KatoIII
cells. The b-cateninHi population (Q2 and Q4) was
set as the top 50% level in the control KatoIII cells.
(b) Proportion of the b-cateninHi and b-cateninLo
cells in the control cells (control) or RUNX3Lo and
RUNX3Hi of the RUNX3-transfected cells.
(c) Immunocytochemistry for RUNX3 (green, left)
and b-catenin (red, center) and a merged image
(right) with DAPI staining (blue) of RUNX3-
transfected KatoIII cells. Arrows, RUNX3 and
b-catenin double-positive cells.
© 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd
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TCF in the nucleus, and recruits cofactors such as Bcl9 and
pygopus to the TCF4 ⁄b-catenin complex, inducing target
gene transcription.(8,21,22) It has also been reported that addi-
tional factors are required for the recruitment of b-catenin to
the target gene promoters. Transducin b-like protein 1
(TBL1) and its related family member, TBLR1, recruit b-
catenin to TCF on the Wnt target gene promoter.(22,23)
TBL1 can bind both TCF4 and b-catenin, suggesting that it
strengthens their physical association, which may contribute
to Wnt activation. Jerky also recruits b-catenin to chromatin,
and promotes the association of b-catenin and LEF1, result-
ing in the induction of Wnt target gene expression.(22,24) We
found that RUNX3 increases the occupancy of the TCF4 ⁄b-
catenin complex in KatoIII cells, suggesting that RUNX3
plays a role in the stabilization of the TCF4 ⁄b-catenin com-
plex on the Wnt target gene promoter like TBL1 and Jerky.
It is also possible that RUNX3 is involved in the recruit-
ment of b-catenin to TCF4 on the Wnt target gene promoter
like these molecules. We have previously shown that the
Wnt activation levels are oscillating in the individual KatoIII
cells,(18) and in this study, we showed that the RUNX3
expression increases the ratio of the Wnt-high population.
Accordingly, it is conceivable that RUNX3 maintains the
Wnt activation at a high level, suppressing the decrease of
Wnt activity by stabilizing the TCF4 ⁄b-catenin complex on
the Wnt target gene promoters.
Another unsolved question is how the RUNX3 ⁄TCF4 com-
plex can bind to the DNA of the Wnt target gene promoter
in KatoIII cells. As previously described, RUNX3-bound
TCF4 cannot bind chromatin, possibly due to the competi-
tion for the DNA binding region of TCF4 with RUNX3. It
is possible that cofactor(s) in the complex affect the confor-
mation of the RUNX3 ⁄TCF4 ⁄b-catenin complex. Genetic
polymorphisms of such cofactor(s) may cause conformational
changes of the complex, which allows RUNX3-bound TCF4
to bind the Wnt target gene promoter. It would be worth
examining the DNA sequences of cofactors of the TCF4 ⁄b-
catenin complex in KatoIII and SNU668 cells to understand
the molecular mechanism(s) responsible for the RUNX3-
associated Wnt regulation.
In the present study, we also confirmed that RUNX3 trans-
fection significantly suppressed the proliferation and tumorige-
nicity of KatoIII cells with induction of p21 expression.
Moreover, RUNX3 has been shown to induce the apoptosis of
gastric cancer cells by upregulating apoptosis-related genes.(25)
It is thus possible that these gene products suppressed the pro-
liferation and survival of RUNX3Hi-expressing KatoIII cells,
and that RUNX3-induced Wnt activation is not sufficient to
protect KatoIII cells from RUNX3-induced apoptosis. It
remains to be investigated whether RUNX3 suppresses tumori-
genicity also in SNU668 cells. However, it has been reported
that RUNX3 is upregulated and functions as an oncogene in
head and neck cancer cells by increasing the proliferation and
sphere formation.(26,27) Accordingly, the RUNX3-associated
tumor suppressing functions are likely inactivated in head and
neck cancer cells, and, therefore, it is possible that RUNX3-
associated Wnt activation contributes to tumorigenesis in such
cancer cells.
The present results, together with previous findings,(12,13)
indicate that RUNX3 can either suppress or activate Wnt sig-
naling through binding to the TCF4 ⁄b-catenin complex.
Although it remains to be investigated, cofactor(s) that bind
the RUNX3 ⁄TCF4 ⁄b-catenin complex may be involved in the
decision regarding the direction of Wnt signaling modulation;
that is, suppression or activation.
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Supporting Information
Additional supporting information may be found in the online version of this article:
Fig. S1. Relative RUNX3 mRNA levels in gastric cancer cell lines examined by RT-PCR.
Fig. S2. Western blotting results of RUNX3 and active form of b-catenin in KatoIII cells and KatoIII-R3 cells.
Fig. S3. Relative band intensities calculated from the Western blotting results (Fig. 2b) of active b-catenin and RUNX3 in the RUNX3 expression
vector-transfected KatoIII cells.
Fig. S4. Flow cytometry analyses of b-catenin and GFP in the control KatoIII cells and GFP expression vector-transfected KatoIII cells.
Fig. S5. Cell proliferation rates of RUNX3 siRNA-transfected KatoIII-R3 cells.
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